All In Biotech

Drug Trial Radar · NCT04480567

AAV Gene Therapy Study for Subjects with PKU

A Phase 1/2 Open-Label, Dose Escalation Study to Determine the Safety and Efficacy of BMN 307, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Phenylalanine Hydroxylase in Subjects with Phenylketonuria

Last checked: Nov 19, 2026Latest source record: Dec 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Sep 24, 2020

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
BioMarin PharmaceuticalBioMarin (BMRN)
Sponsor type
Industry
First posted
Jul 21, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2, open-label, dose escalation study to evaluate the safety, efficacy and tolerability of BMN 307 in adult PKU subjects with PAH deficiency. Participants will receive a single administration of BMN 307 and will be followed for safety and efficacy.

Conditions

  • Phenylketonuria (PKU)

Interventions

  • BMN 307Drug

    AAV Gene Therapy Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in mean Plasma Phe levelsTime frame: baseline, week 12

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • University of South Florida

    Tampa, Florida

  • Morristown Medical Center

    Morristown, New Jersey

  • University Hospital Birmingham NHS Foundation Trust

    Birmingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.